Lineage Cell Therapeutics Q2 revenue falls but posts profit

LCTX•2026-08-06

COLLABORATION REVENUE DECLINE - Co said lower Q2 revenue was mainly due to reduced collaboration revenue recognized from deferred revenues under the Roche Agreement and the prior year termination of the VAC platform-related collaboration
OPERATING EXPENSES DROP - Co attributed lower operating expenses to the absence of last year's $14.8 mln non-cash impairment expense related to the VAC platform
WARRANT LIABILITY REMEASUREMENT - Co said net income was helped by a favorable quarterly fair value remeasurement of warrant liabilities driven by a decrease in share price

US cell therapy developer's Q2 revenue declined yr/yr due to lower collaboration revenue
Q2 net income reached $1.5 mln, reversing a loss from the prior year period
Operating expenses fell sharply, reflecting absence of prior year impairment charge

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Net Income		$1.54 mln
Q2 Income from Operations		-$8.92 mln
Q2 Operating Expenses		$9.99 mln

Related News